Anti-Mouse CD276/B7-H3 Antibody (MJ18)
Based on 1 Customer Validation
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer.
For research use only. We do not sell to patients.
- Purity : 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
[1]|
p-STAT3 |
In Vivo
Anti-Mouse CD276/B7-H3 Antibody (MJ18) (160 μg, i.p., twice weekly, for 2 weeks) significantly inhibits tumor growth and increases CD8+ T cell infiltration in female BALB/c mice bearing 4T1 tumors[2].
Anti-Mouse CD276/B7-H3 Antibody (MJ18) (10 mg/kg, i.p., three times a week, for 4 weeks) significantly inhibits tumor growth, synergistically increases CD8+ T cell infiltration and tumor cell apoptosis in Rosa-CD276 C57BL/6 mice induced with N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) (HY-W755252)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The Squamouth Cell Carcinomas of the Head and Neck model consists of Tgfbr1/Pten 2cKO mice induced with Tamoxifen (2 mg/kg, p.o., for 5 days)[1]
-
Dosage:0.3 mg/mouse
-
Administration:Intraperitoneal injection (i.p.), once every other day, from day 14 to 30
-
Result:Significantly inhibited tumor growth and reduced tumor burden.
Reduced lymph node enlargement and spleen index.
Reduced the expression of p-STAT3, CXCL1, CCL2, and B7-H3.
Reduced myeloid-derived suppressor cells (MDSCs) and tumour-associated macrophages (TAMs) and enhanced T cell activity.
-
Animal Model:1×107 4T1 cells injected female BALB/c mice (5-6 weeks)[2]
-
Dosage:160 μg, combined with TVB-3166 (30 mg/kg, p.o., once daily) (HY-120394) and PD-L1 mAb (200 μg, i.p., twice weekly)
-
Administration:Intraperitoneal injection (i.p.), twice weekly for 2 weeks
-
Result:Inhibited tumor growth and upregulated FASN expression within tumors.
Increased CD8+ T cell infiltration and tumor cell apoptosis.
-
Animal Model:The bladder cancer consists of BBN induced Rosa-CD276 C57BL/6 mice[3]
-
Dosage:10 mg/kg, combined with anti-PD-L1 (200 μg/mouse, on day 1, 3, 5, 7 and 14)
-
Administration:Intraperitoneal injection (i.p.), three times a week for 4 weeks
-
Result:Significantly inhibited the volume of tumors.
Increased CD8+ T cell infiltration and tumor cell apoptosis.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo B7-H3 blockade; Flow cytometry
Verified Bioactivity
-
Loaded Anti-Mouse CD276/B7-H3 Antibody (MJ18) on CM5 biosensor, can bind CD276/B7-H3 Protein, Mouse (HEK293, His, HY-P7639) with an affinity constant of 5.28E-07 M as determined in SPR assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD276/B7-H3 Antibody (MJ18)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Mao L, et al. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. J Cell Mol Med. 2017 Sep;21(9):2199-2210. [Content Brief]
[2]. Jiang Y, et al. Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. J Immunother Cancer. 2025 Apr 12;13(4):e010924. [Content Brief]
[3]. Cheng M, et al. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. Nat Commun. 2024 Apr 1;15(1):2818. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD276/B7-H3 Antibody (MJ18) Related Classifications
HY-P990279 Related Classifications
Powered by Bioz